Metastatic Bone Disease
Metastatic Bone Disease - Related Videos
08:49
Models of Bone Metastasis
0 Views •
Cited by 115 •
2012
Animal models are frequently utilized to study cancer metastasis to bone. In this protocol we will describe two common methods of tumor inoculation for bone metastasis studies and briefly describe some of the analyses utilized to monitor and quantify these models.
03:52
Experimental Metastatic Melanoma Mouse Model: A Platform to Study the Metastatic Potential of Melanoma Cells in the Lungs
0 Views •
2023
In this video, melanoma cells are intravenously injected through the tail vein in the mouse model. The melanoma cells further travel through the circulatory system, adapting to the distant microenvironment and causing metastasis in organs like lungs.
11:27
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
0 Views •
Cited by 23 •
2014
Models of spontaneous metastatic renal cell carcinoma (RCC) disease progression can be used for evaluating treatments in a clinically relevant setting. This protocol demonstrates different procedures for orthotopic kidney tumor cell implantation, proper nephrectomy, and finally outlines a necropsy guide for visual and bioluminescent scoring of metastatic burden and localization.
09:14
An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
0 Views •
Cited by 39 •
2011
A modified 3-D in vitro system is presented in which growth characteristics of several tumor cell lines in reconstituted basement membrane correlate with the dormant or proliferative behavior of the tumor cells at a metastatic secondary site in vivo.
05:54
Induction of Graft Versus Host Disease in Mouse Models via Allogeneic Bone Marrow and Splenic Cell Transplantation
0 Views •
2025
This video demonstrates the induction of intestinal graft-versus-host disease, GvHD, in a lethally-irradiated recipient mouse using allogeneic hematopoietic stem cells and GvHD-inducing splenic alloreactive T lymphocytes. This protocol helps establish a severe acute intestinal GvHD model to understand the mechanism of the disease and develop innovative therapeutic options.
FAQs
Malignant cells in bone can disturb normal remodeling, while the altered bone environment supports further tumor growth. This reciprocal interaction forms a tumor–bone feedback cycle rather than a one-directional spread. As the cycle continues, local skeletal damage and tumor progression can reinforce one another, helping explain why established lesions may produce increasingly serious bone-related consequences.
Osteoclast-mediated resorption and osteoblast-mediated formation normally contribute to skeletal remodeling. Metastatic lesions disrupt this balance, so bone may be damaged or rebuilt abnormally around tumor deposits. This imbalance is clinically important because it links the biology of the lesion to loss of skeletal integrity and to complications that affect function and quality of life.
Once circulating tumor cells establish secondary lesions in bone marrow, skeletal involvement can manifest through several complications. Patients may develop pain, fractures, hypercalcemia, or spinal cord compression. These outcomes represent different consequences of tumor-associated bone disruption and are important because they can impair mobility, skeletal function, and overall quality of life.
Evaluation combines symptoms with imaging and laboratory tests to assess the clinical and skeletal consequences of disease. In some cases, clinicians also obtain a biopsy, which provides tissue for confirming the lesion. Bringing these sources of information together helps guide management rather than relying on a single symptom, scan, or laboratory result.
Radiation and surgery provide local approaches within a broader treatment plan. They may be considered alongside systemic anticancer therapy and medicines such as bisphosphonates or denosumab. The selected options depend on clinical evaluation and treatment objectives, including controlling disease, preserving skeletal function, reducing complications, and supporting quality of life.
Combining treatment types allows care to address different clinical priorities. Systemic anticancer therapy can be included to control tumor growth, while radiation, surgery, bisphosphonates, or denosumab may form part of a plan focused on skeletal function and complications. This approach addresses both the underlying malignancy and the consequences of its involvement in bone.